Literature DB >> 29725697

The impact of phosphatases on proliferative and survival signaling in cancer.

Goutham Narla1, Jaya Sangodkar2, Christopher B Ryder3.   

Abstract

The dynamic and stringent coordination of kinase and phosphatase activity controls a myriad of physiologic processes. Aberrations that disrupt the balance of this interplay represent the basis of numerous diseases. For a variety of reasons, early work in this area portrayed kinases as the dominant actors in these signaling events with phosphatases playing a secondary role. In oncology, these efforts led to breakthroughs that have dramatically altered the course of certain diseases and directed vast resources toward the development of additional kinase-targeted therapies. Yet, more recent scientific efforts have demonstrated a prominent and sometimes driving role for phosphatases across numerous malignancies. This maturation of the phosphatase field has brought with it the promise of further therapeutic advances in the field of oncology. In this review, we discuss the role of phosphatases in the regulation of cellular proliferation and survival signaling using the examples of the MAPK and PI3K/AKT pathways, c-Myc and the apoptosis machinery. Emphasis is placed on instances where these signaling networks are perturbed by dysregulation of specific phosphatases to favor growth and persistence of human cancer.

Entities:  

Keywords:  Apoptosis; MAPK; PI3K; PP2A; Phosphorylation; c-Myc

Mesh:

Substances:

Year:  2018        PMID: 29725697      PMCID: PMC6023766          DOI: 10.1007/s00018-018-2826-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  276 in total

1.  Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes.

Authors:  Svante Resjö; Olga Göransson; Linda Härndahl; Stanislaw Zolnierowicz; Vincent Manganiello; Eva Degerman
Journal:  Cell Signal       Date:  2002-03       Impact factor: 4.315

2.  Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

Authors:  Jaya Sangodkar; Abbey Perl; Rita Tohme; Janna Kiselar; David B Kastrinsky; Nilesh Zaware; Sudeh Izadmehr; Sahar Mazhar; Danica D Wiredja; Caitlin M O'Connor; Divya Hoon; Neil S Dhawan; Daniela Schlatzer; Shen Yao; Daniel Leonard; Alain C Borczuk; Giridharan Gokulrangan; Lifu Wang; Elena Svenson; Caroline C Farrington; Eric Yuan; Rita A Avelar; Agnes Stachnik; Blake Smith; Vickram Gidwani; Heather M Giannini; Daniel McQuaid; Kimberly McClinch; Zhizhi Wang; Alice C Levine; Rosalie C Sears; Edward Y Chen; Qiaonan Duan; Manish Datt; Shozeb Haider; Avi Ma'ayan; Analisa DiFeo; Neelesh Sharma; Matthew D Galsky; David L Brautigan; Yiannis A Ioannou; Wenqing Xu; Mark R Chance; Michael Ohlmeyer; Goutham Narla
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

Review 3.  The essential role of evasion from cell death in cancer.

Authors:  Gemma L Kelly; Andreas Strasser
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

Review 4.  Signalling by protein phosphatases and drug development: a systems-centred view.

Authors:  Lan K Nguyen; David Matallanas; David R Croucher; Alexander von Kriegsheim; Boris N Kholodenko
Journal:  FEBS J       Date:  2012-03-14       Impact factor: 5.542

5.  Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress.

Authors:  K Morita; M Saitoh; K Tobiume; H Matsuura; S Enomoto; H Nishitoh; H Ichijo
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

6.  Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation.

Authors:  Lisa Polzien; Angela Baljuls; Ulrike E E Rennefahrt; Andreas Fischer; Werner Schmitz; Rene P Zahedi; Albert Sickmann; Renate Metz; Stefan Albert; Roland Benz; Mirko Hekman; Ulf R Rapp
Journal:  J Biol Chem       Date:  2009-08-10       Impact factor: 5.157

7.  Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers.

Authors:  Y Seo; T Matozaki; M Tsuda; Y Hayashi; H Itoh; M Kasuga
Journal:  Biochem Biophys Res Commun       Date:  1997-02-24       Impact factor: 3.575

8.  Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation.

Authors:  Hugh K Arnold; Rosalie C Sears
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  The characteristic gene expressions of MAPK phosphatases 1 and 2 in hepatocarcinogenesis, rat ascites hepatoma cells, and regenerating rat liver.

Authors:  A Yokoyama; H Karasaki; N Urushibara; K Nomoto; Y Imai; K Nakamura; Y Mizuno; K Ogawa; K Kikuchi
Journal:  Biochem Biophys Res Commun       Date:  1997-10-29       Impact factor: 3.575

10.  The anti-apoptotic molecules Bcl-xL and Bcl-w target protein phosphatase 1alpha to Bad.

Authors:  Verónica Ayllón; Xavier Cayla; Alphonse García; Aarne Fleischer; Angelita Rebollo
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

View more
  6 in total

Review 1.  Targeting PP2A in cancer: Combination therapies.

Authors:  Sahar Mazhar; Sarah E Taylor; Jaya Sangodkar; Goutham Narla
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-01       Impact factor: 4.739

2.  Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr307 on PP2Ac.

Authors:  Sahar Mazhar; Daniel Leonard; Alejandro Sosa; Daniela Schlatzer; Dafydd Thomas; Goutham Narla
Journal:  Cell Rep       Date:  2020-03-03       Impact factor: 9.423

3.  The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Authors:  Erika Parasido; George S Avetian; Aisha Naeem; Garrett Graham; Michael Pishvaian; Eric Glasgow; Shaila Mudambi; Yichien Lee; Chukwuemeka Ihemelandu; Muhammad Choudhry; Ivana Peran; Partha P Banerjee; Maria Laura Avantaggiati; Kirsten Bryant; Elisa Baldelli; Mariaelena Pierobon; Lance Liotta; Emanuel Petricoin; Stanley T Fricke; Aimy Sebastian; Joseph Cozzitorto; Gabriela G Loots; Deepak Kumar; Stephen Byers; Eric Londin; Analisa DiFeo; Goutham Narla; Jordan Winter; Jonathan R Brody; Olga Rodriguez; Chris Albanese
Journal:  Mol Cancer Res       Date:  2019-06-04       Impact factor: 5.852

4.  IGF‑IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway.

Authors:  Qi He; Qingqing Zheng; Feng Xu; Wenhui Shi; Juan Guo; Zheng Zhang; Sida Zhao; Xiao Li; Chunkang Chang
Journal:  Oncol Rep       Date:  2020-06-19       Impact factor: 3.906

5.  The synergistic effect of 2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside combined with Adriamycin on MCF-7 breast cancer cells.

Authors:  Jianfen Shen; Youzhi Zhang; Hui Shen; Hua Pan; Longsheng Xu; Linna Yuan; Zhiying Ding
Journal:  Drug Des Devel Ther       Date:  2018-11-30       Impact factor: 4.162

6.  From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.

Authors:  Mahsa Saliani; Razieh Jalal; Mohammad Reza Ahmadian
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.